Skip to main content
Premium Trial:

Request an Annual Quote

Genaissance, Organon to Develop Dx for Psychiatric Drug Response

NEW YORK, July 18 (GenomeWeb News) - Genaissance Pharmaceuticals and Organon will jointly study genetic markers related to drug response in certain undisclosed psychiatric disorders, and plan to develop diagnostics based on the resulting data, the companies said today.

 

Under the agreement, Organon will license Genaissance's HAP technology and will pay the company fees for genotyping samples from clinical trials and for research. Genaissance will also provide DNA isolation and sample banking for the trials.

 

In addition to providing services, Genaissance has certain rights to develop and commercialize genetic tests accompanying therapy. Both companies will share royalties on revenues generated from such tests.

 

Organon, a business unit of Akzo Nobel, is based in Roseland, NJ. It focuses on reproductive medicine, psychiatry, and anesthesia.

The Scan

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.

Analysis of Endogenous Parvoviral Elements Found Within Animal Genomes

Researchers at PLOS Biology have examined the coevolution of endogenous parvoviral elements and animal genomes to gain insight into using the viruses as gene therapy vectors.

Saliva Testing Can Reveal Mosaic CNVs Important in Intellectual Disability

An Australian team has compared the yield of chromosomal microarray testing of both blood and saliva samples for syndromic intellectual disability in the European Journal of Human Genetics.

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.